Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALX-0081

Known as: ALX 0081, ALX0681, ALX0081 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

caplacizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Balancing Scattering Channels: A Panoscopic Approach toward Zero Temperature Coefficient of Resistance Using High-Entropy Alloys.
Designing alloys with an accurate temperature-independent electrical response over a wide temperature range, specifically a low… Expand
2017
2017
Composite Electrolyte for All-Solid-State Lithium Batteries: Low-Temperature Fabrication and Conductivity Enhancement.
All-solid-state lithium batteries offer notable advantages over conventional Li-ion batteries with liquid electrolytes in terms… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs.
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2012
Highly Cited
2012
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.
ALX-0681 is a therapeutic Nanobody targeting the A1-domain of VWF. It inhibits the interaction between ultra-large VWF and… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2011
Highly Cited
2011
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.
Neutralizing the interaction of the platelet receptor gpIb with VWF is an attractive strategy to treat and prevent thrombotic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.
Compound ALX-0081 is a bivalent humanised Nanobody® that binds the A1-domain of von Willebrand factor (VWF) with high affinity… Expand
Review
2010
Review
2010
Targeting von Willebrand factor and platelet glycoprotein Ib receptor
Atherothrombotic events, such as acute coronary syndrome or stroke, are the result of platelet activation. Von Willebrand factor… Expand
2009
2009
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody® ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.
ALX-0681 is a humanized bivalent Nanobody®, that binds to the A1 domain of von Willebrand factor (vWF) and hence blocks its… Expand
2006
2006
ALX-0081 Nanobody™, an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.
In patients with plaque rupture, platelets adhere, aggregate and form a thrombus. Current strategies to prevent thrombus… Expand
2002
2002
Positron Lifetime Study of Defect Structures in B2 Ordered Co-Al Alloys
The positron lifetimes in the B2 intermetallic compounds Co100−XAlX (X=46.9 to 54.1) water-quenched, air- and furnace-cooled from… Expand
  • figure 1
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE